@Mind_Da_GAAP If top executives moved, it's to close the deal (or start talks, but it's too late for that) and closing happens at the HQs, followed by a nice PR. It doesn't happen on the CEO's porch.
@puppyeh1 Both sides of the argument contain some truth.
Not all change is progress and the Cantillon effect and its destructive consequences are real.
Moreover two fundamentally opposed forces are at work in the economy - the market and the state - and their effects overlap and diverge.
@Ssunten_ Excellent work. Any input on $OTLK? Seems higher risk, considering the contents of its CRL and the recent FDA drama, but potentially higher reward too and is flying under the radar, maybe on account of its small mktcap and treatment alternatives already available in wet ADM.
@FibSixOne8 To be honest $MMET.V and $GHRT.V were/are much worse.
I don't see $SRAN.CN's valuation as outrageous. Am I a buyer here? No, but I am keeping an eye on it in case they hit. Good team and promising ground.
@VukasinPekovic@Pete__Panda I agree that GHRT looks better, but I wouldn't be a buyer here at >CAD 100m mkt cap, still room to fall.
I am watching SRAN with interest, but I want to see hits before buying. Hard to justify when you can still buy RAMP at CAD 70m mkt cap with cash on hand and 2nd assays pending
@VukasinPekovic@Pete__Panda GHRT also suffered a re-rate following first drilling results. Will SRAN be next? So far it doesn't look overhyped like the first two.
@virologyanon@akarlin Nothing of significance will happen in the field until immunosenescence and specifically thymic involution are properly recognized as major drivers of ageing, which in turn implies taking a look at microbial load and chronic subclinical infections by presumed """commensals""".